The EMA CHMP has recommended the marketing authorization for the mRNA RSV vaccine mRESVIA to protect adults aged 60 or older from lower respiratory tract disease caused by RSV. RSV is a contagious respiratory virus that can lead to serious consequences in older adults. The vaccine, mRNA-1345, targets the F glycoprotein of RSV to prevent infection. The CHMP decision was based on a study showing the vaccine’s effectiveness in preventing lower respiratory tract disease in older people. The CHMP also supported updating the Comirnaty mRNA vaccine to target the new SARS-CoV-2 JN.1 variant for the 2024-2025 vaccination campaign to maintain vaccine effectiveness as the virus evolves.
Source link
Europe Endorses Its First mRNA Vaccine for RSV
